Astrazeneca Ab

Scott Boyd

Craig Johnstone

Roger James

Clifford David Jones

Michael Howard Block

Rodney Brian Hargreaves

Suzanne Saxon Bowker

Peter William Rodney Caulkett

Darren McKerrecher

Jason Grant Kettle

Kurt G Pike

Iain Simpson

Darren Mckerrecher

Michael Steven Bodnarchuk

Doyle Joseph Cassar

Oliver Ross Steward

Christopher Phillips

Kurt Gordon Pike

The specification relates to compounds of Formula (A) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Fused tricyclic compounds useful as anticancer agents

The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R, R, R, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

Compounds effecting glucokinase

The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R, R, R, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes.  The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

Growing community of inventors

Cheshire, United Kingdom

Scott Boyd